Time limited offer for new users ▶ Get up to 3 months free

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Moodys
McKinsey
Mallinckrodt
Dow
AstraZeneca

Last Updated: January 27, 2023

CLINICAL TRIALS PROFILE FOR BROMFENAC SODIUM


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


All Clinical Trials for Bromfenac Sodium

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00198445 ↗ Safety and Efficacy Study of Topical Bromfenac Versus Placebo to Treat Ocular Inflammation After Cataract Surgery Completed Bausch & Lomb Incorporated Phase 3 2003-05-01 The primary objective of this study was to investigate the efficacy of bromfenac sodium ophthalmic solution 0.09% for treatment of post-operative ocular inflammation in subjects who undergo cataract extraction and intraocular lens implantation. The secondary objective was to investigate the safety and tolerability of the same.
NCT00595543 ↗ Treatment of Acute Pseudophakic Cystoid Macular Edema: Bromfenac 0.09% Versus Diclofenac Sodium 0.1% Versus Ketorolac Tromethamine 0.5% Completed Bp Consulting, Inc Phase 4 2008-01-01 To compare bromfenac 0.09%, diclofenac sodium 0.1%, and ketorolac tromethamine 0.5% ophthalmic solutions for the treatment of acute pseudophakic CME after cataract surgery.
NCT01387464 ↗ Aqueous Humor Concentration of InSite Vision (ISV) 303 (Bromfenac in DuraSite) to Bromday Once Daily (QD) Prior to Cataract Surgery Completed InSite Vision Phase 2 2011-07-01 The purpose of this study is to evaluate the aqueous humor concentration of bromfenac sodium in subjects administered multiple topical ocular doses of ISV-303 or Bromday™ QD prior to routine cataract surgery.
NCT01387464 ↗ Aqueous Humor Concentration of InSite Vision (ISV) 303 (Bromfenac in DuraSite) to Bromday Once Daily (QD) Prior to Cataract Surgery Completed Sun Pharma Global FZE Phase 2 2011-07-01 The purpose of this study is to evaluate the aqueous humor concentration of bromfenac sodium in subjects administered multiple topical ocular doses of ISV-303 or Bromday™ QD prior to routine cataract surgery.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Bromfenac Sodium

Condition Name

Condition Name for Bromfenac Sodium
Intervention Trials
Cataract 3
Atrial Fibrillation 1
Familial Exudative Vitreoretinopathies 1
Postoperative Complications 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Bromfenac Sodium
Intervention Trials
Cataract 3
Inflammation 1
Retinal Diseases 1
Familial Exudative Vitreoretinopathies 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Bromfenac Sodium

Trials by Country

Trials by Country for Bromfenac Sodium
Location Trials
United States 25
China 1
Brazil 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Bromfenac Sodium
Location Trials
Pennsylvania 2
Oregon 1
Kentucky 1
Louisiana 1
Massachusetts 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Bromfenac Sodium

Clinical Trial Phase

Clinical Trial Phase for Bromfenac Sodium
Clinical Trial Phase Trials
Phase 4 2
Phase 3 1
Phase 2 2
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Bromfenac Sodium
Clinical Trial Phase Trials
Completed 5
Not yet recruiting 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Bromfenac Sodium

Sponsor Name

Sponsor Name for Bromfenac Sodium
Sponsor Trials
Bausch & Lomb Incorporated 1
Bp Consulting, Inc 1
InSite Vision 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Bromfenac Sodium
Sponsor Trials
Other 6
Industry 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
AstraZeneca
Colorcon
McKesson
McKinsey
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.